Twist Bioscience (NASDAQ:TWST) Price Target Lowered to $44.00 at Robert W. Baird

Twist Bioscience (NASDAQ:TWST) had its target price decreased by Robert W. Baird from $54.00 to $44.00 in a report issued on Tuesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research firms also recently issued reports on TWST. Guggenheim set a $50.00 target price on Twist Bioscience in a research report on Friday, March 28th. Barclays lowered their price target on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. JPMorgan Chase & Co. decreased their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Tuesday. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.40.

Twist Bioscience Price Performance

TWST opened at $32.75 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The stock has a market capitalization of $1.95 billion, a P/E ratio of -9.69 and a beta of 2.54. The company’s 50 day simple moving average is $39.02 and its 200-day simple moving average is $43.90. Twist Bioscience has a one year low of $32.63 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million during the quarter, compared to the consensus estimate of $92.00 million. Sell-side analysts anticipate that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of Twist Bioscience stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $98,265.82. Following the transaction, the chief executive officer now owns 662,692 shares of the company’s stock, valued at $27,110,729.72. This represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,137 shares of company stock valued at $530,112. 3.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently modified their holdings of TWST. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Twist Bioscience during the 1st quarter valued at $326,000. Allianz Asset Management GmbH lifted its holdings in Twist Bioscience by 6.3% during the first quarter. Allianz Asset Management GmbH now owns 17,000 shares of the company’s stock valued at $667,000 after purchasing an additional 1,000 shares during the last quarter. CWM LLC boosted its position in Twist Bioscience by 161.4% during the first quarter. CWM LLC now owns 16,272 shares of the company’s stock worth $639,000 after purchasing an additional 10,048 shares during the period. New York State Common Retirement Fund increased its stake in shares of Twist Bioscience by 2.4% in the first quarter. New York State Common Retirement Fund now owns 452,750 shares of the company’s stock worth $17,775,000 after purchasing an additional 10,761 shares in the last quarter. Finally, Xponance Inc. raised its position in shares of Twist Bioscience by 22.0% in the first quarter. Xponance Inc. now owns 5,953 shares of the company’s stock valued at $234,000 after purchasing an additional 1,072 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.